FDA stiff arms Evolus’ rival to Allergan’s blockbuster Botox, but execs promise a snap response

Evolus’ $EOLS attempt to field a rival to Allergan’s Botox has run into problems at the FDA.

The biotech announced Wednesday morning that the FDA has handed the company a complete response letter for DWP-450 (prabotulinumtoxinA).